• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Elbow Erosions

News
Poll

A pruritic, scaly rash appeared on this 42-year-old man's elbows, knees, lower back, and buttocks. Can you ID?

A 42-year-old man presents with a pruritic rash characterized by pink, scaly plaques with a few crusted erosions on the elbows (Figure) knees, lower back, and buttocks. Review of systems was negative, although there was a strong positive family history of celiac disease. He took no medications and was otherwise healthy.

 

Which of the following do you suspect?

A. Dermatitis herpetiformis
B. Bullous pemphigoid
C. Granuloma annulare
D. Granulomatous dermatitis
E. Palisaded neutrophilic dermatitis
Related Content
Evidence-Based Management of Papulosquamous Disorders in Primary Care / image credit ©Daniel Beckemeier/stock.adobe.com

Evidence-Based Management of Papulosquamous Disorders in Primary Care

Grace Halsey
October 7th 2025
Article

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
August 25th 2025
Podcast

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults / image credit ©Waldenmarus/stock.adobe.com

Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults

Grace Halsey
October 2nd 2025
Article

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care / image credit ©designua/stock.adobe.com

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care

Patient Care Editorial Staff
September 24th 2025
Article

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b RESOLVE-AD Trial / image courtesy of George Washington University School of Medicine

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b REZOLVE-AD Trial

Grace Halsey
September 23rd 2025
Article

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

© 2025 MJH Life Sciences

All rights reserved.